Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation.

Content Provider	Europe PMC
Author	Rai, Shinya Tanaka, Hirokazu Espinoza, J. Luis Kumode, Takahiro Matsumura, Itaru
Copyright Year	2021
Abstract	Acute myeloid leukemia (AML) is a heterogeneous disease often associated with poor prognosis. We previously showed that the localization of KIT-D816V at endolysosomes is critical to activate aberrant Akt signaling and Chlorpromazine (CPZ) perturbs the intracellular localization, leading to cell death in AML cells with KIT-D816V. We report that daily administration of CPZ, prescribed for controlling anxiety disorder in patient with AML harboring KIT-D816V, led to a dramatic reduction in AML cells. In vitro and in vivo experiments showed that CPZ inhibited the growth and survival of the patient-derived AML cells, implying potent efficacy of CPZ in AML with KIT-D816V.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8233227&blobtype=pdf
Journal	Leukemia Research Reports [Leuk Res Rep]
Volume Number	15
DOI	10.1016/j.lrr.2021.100256
PubMed Central reference number	PMC8233227
PubMed reference number	34194969
e-ISSN	22130489
Language	English
Publisher	Elsevier
Publisher Date	2021-06-12
Access Restriction	Open
Rights License	This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). © 2021 The Authors. Published by Elsevier Ltd.
Subject Keyword	Acute myeloid leukemia Kit-d816v Chlorpromazine Intracellular trafficking Receptor tyrosine kinase
Content Type	Text
Resource Type	Article
Subject	Hematology Oncology